{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:10:21Z","timestamp":1753891821893,"version":"3.41.2"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>In neuro-oncological pediatric patients under 3 years of age, chemotherapy intensified to high doses (high-dose chemotherapy, HDC) represents the cornerstone to avoid the potential toxicity of radiotherapy. Combination treatment with gemcitabine\u2013oxaliplatin (GemOx) was administered for infant- type cerebral tumors as a bridge toward autologous hematopoietic transplantation to achieve clinical and neuroradiological permissiveness to HDC and to raise the possibility of second-look neurosurgery. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>From May 2017 to May 2023, at Meyer Children\u2019s Hospital IRCSS in Florence (Italy), four patients, with a median age of 19 months (with two high- grade gliomas, a metastatic medulloblastoma, and a choroid plexus carcinoma CNS WHO grade 3), were subjected to partial neurosurgical removal and induction therapy delivered according to the Italian program for malignant cerebral tumors under 3 years. To delay HDC, either for disease reassessment or for temporary unfitness, GemOx cycles were administered. Gemcitabine 1,000 mg\/m2 and oxaliplatin 100 mg\/m2 were given on day 1 every 21\u201328 days for one to six cycles. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The treatment was well tolerated overall, except for severe platelet hematological toxicity in a patient, which required dose reduction to 75%. After GemOx, one patient was also subjected to further neurosurgery. Bridge therapy made it possible to submit patients to HDC in safety, in permissive clinical conditions, and after assessment of disease stability. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In infant-type cerebral tumors eligible for HDC, GemOx could be a possible strategy in the case of post-induction residual disease to exclude uncertain evolution or when waiting for clinical suitability for second surgery and intensified treatment. The therapy was overall safe and well tolerated. This approach resulted incisive in the therapeutic or palliative choice for extremely young patients with aggressive brain tumors.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1476411","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T05:29:09Z","timestamp":1747114149000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Gemcitabine\u2013oxaliplatin as a bridge therapy toward autologous hematopoietic stem cell transplantation in infant-type brain tumors"],"prefix":"10.3389","volume":"15","author":[{"given":"Barbara","family":"Castelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Fonte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Tellini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Di Nicola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milena","family":"Guidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Giunti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca","family":"Tirinnanzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Marzano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Maria","family":"Buccoliero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludovico","family":"D\u2019Incerti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavio","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirko","family":"Scagnet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Tintori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Genitori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iacopo","family":"Sardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1179\/joc.2010.22.5.298","article-title":"Gemox: A widely useful therapy against solid tumors-review and personal experience","volume":"22","author":"Meriggi","year":"2010","journal-title":"J Chemother"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00331.2022","article-title":"Barriers and opportunities for gemcitabine in pancreatic cancer therapy","volume":"324","author":"Beutel","year":"2023","journal-title":"Am J Physiology-Cell Physiol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S3583","article-title":"Role of oxaliplatin in the treatment of colorectal cancer","volume":"229","author":"Comella","year":"2009","journal-title":"TCRM"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.09.015","article-title":"Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid Malignancies: An innovative therapy for children with Cancer European Consortium Study","volume":"47","author":"Geoerger","year":"2011","journal-title":"Eur J Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604628","article-title":"Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study","volume":"99","author":"Andr\u00e9","year":"2008","journal-title":"Br J Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e30214","DOI":"10.1002\/pbc.30214","article-title":"Use of gemcitabine, oxaliplatin, and anti-CD20 therapy in children and adolescents with non-Hodgkin lymphoma unfit for intensive therapy","volume":"70","author":"Bender","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2020.00135","article-title":"Use of high-dose chemotherapy in front-line therapy of infants aged less than 12 months treated for aggressive brain tumors","volume":"8","author":"Guidi","year":"2020","journal-title":"Front Pediatr"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.4176","article-title":"Hyperfractionated accelerated radiotherapy in the milan strategy for metastatic medulloblastoma","volume":"27","author":"Gandola","year":"2009","journal-title":"JCO"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh351","article-title":"Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study","volume":"15","author":"Andr\u00e9","year":"2004","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.3390\/cancers13143507","article-title":"Real-world evidence on palliative gemcitabine and oxaliplatin (GemOx) combination chemotherapy in advanced biliary tract cancer","volume":"13","author":"Lagenfelt","year":"2021","journal-title":"Cancers"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e001240","DOI":"10.1136\/jitc-2020-001240","article-title":"Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial","volume":"8","author":"Chen","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"175628482311606","DOI":"10.1177\/17562848231160630","article-title":"Efficacy and safety of a triple combination of atezolizumab, bevacizumab plus GEMOX for advanced biliary tract cancer: a multicenter, single-arm, retrospective study","volume":"16","author":"Wang","year":"2023","journal-title":"Therap Adv Gastroenterol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602966","article-title":"Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study","volume":"94","author":"Demols","year":"2006","journal-title":"Br J Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg170","article-title":"Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Groupphase II study","volume":"14","author":"Alberts","year":"2003","journal-title":"Ann Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S220299","article-title":"A retrospective case series of high-intensity focused ultrasound (HIFU) in combination with gemcitabine and oxaliplatin (Gemox) on treating elderly middle and advanced pancreatic cancer","volume":"12","author":"Tao","year":"2019","journal-title":"OTT"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2006.09.001","article-title":"Gemcitabine plus oxaliplatin combination (GEMOX regimen) in pretreated patients with advanced non-small cell lung cancer (NSCLC): A multicenter phase II study","volume":"54","author":"Kakolyris","year":"2006","journal-title":"Lung Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181ffe8ef","article-title":"A phase III randomized trial of gemcitabine\u2013oxaliplatin versus carboplatin\u2013paclitaxel as first-line therapy in patients with advanced non-small cell lung cancer","volume":"6","author":"Weissman","year":"2011","journal-title":"J Thorac Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604878","article-title":"Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group","volume":"100","author":"Ray-Coquard","year":"2009","journal-title":"Br J Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1756-9966-32-49","article-title":"Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients","volume":"32","author":"Vici","year":"2013","journal-title":"J Exp Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4741.2007.00391.x","article-title":"Gemcitabine?Oxaliplatin combination in heavily pretreated metastatic breast cancer: A pilot study on 43 patients","volume":"13","author":"CAruba","year":"2007","journal-title":"Breast J"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1159\/000445936","article-title":"GEMOX: an active regimen for the treatment of luminal and human epidermal growth factor receptor 2-positive metastatic breast cancer","volume":"62","author":"Rizzi","year":"2017","journal-title":"Chemotherapy"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2178-x","article-title":"A phase II study of gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the bladder","volume":"72","author":"Eroglu","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh103","article-title":"Gemcitabine and oxaliplatin (GEMOX) in patients withcisplatin-refractory germ cell tumors: a phase II study","volume":"15","author":"Pectasides","year":"2004","journal-title":"Ann Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp065","article-title":"Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma\u2014correlation with excision repair cross-complementing-1 polymorphisms","volume":"20","author":"Ma","year":"2009","journal-title":"Ann Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v109:7","article-title":"Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): Results of a phase II study","volume":"109","author":"Louafi","year":"2007","journal-title":"Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.09.006","article-title":"Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: A large multicenter AGEO study","volume":"58","author":"Zaanan","year":"2013","journal-title":"J Hepatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30054-1","article-title":"Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial","volume":"5","author":"Shen","year":"2018","journal-title":"Lancet Haematol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3564-6","article-title":"(R)-GEMOX chemotherapy for unfit patients with refractory or recurrent primary central nervous system lymphoma: a LOC study","volume":"98","author":"Collignon","year":"2019","journal-title":"Ann Hematol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02138-X","article-title":"Glofit-GemOx: a new treatment paradigm in relapsed or refractory diffuse large B-cell lymphoma","volume":"404","author":"Sureda","year":"2024","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.285185","article-title":"Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma","volume":"110","author":"Othman","year":"2025","journal-title":"Haematologica"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00066-8","article-title":"First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer\/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial","volume":"11","author":"Tian","year":"2024","journal-title":"Lancet Haematol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04166-z","article-title":"Triple therapy in biliary tract cancers: GemOX plus immune checkpoint inhibitor in combination with lenvatinib or NGS-guided targeted therapy","volume":"149","author":"Dong","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"112872","DOI":"10.1016\/j.intimp.2024.112872","article-title":"Hepatic arterial infusion of GEMOX plus systemic gemcitabine chemotherapy combined with lenvatinib and PD-1 inhibitor in large unresectable intrahepatic cholangiocarcinoma","volume":"140","author":"Ni","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41392-023-01317-7","article-title":"Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study","volume":"8","author":"Shi","year":"2023","journal-title":"Sig Transduct Target Ther"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-017-0492-6","article-title":"Addition of an antiangiogenic therapy, bevacizumab, to gemcitabine plus oxaliplatin improves survival in advanced biliary tract cancers","volume":"36","author":"Br\u00e9chon","year":"2018","journal-title":"Invest New Drugs"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3171\/2014.11.PEDS14334","article-title":"Antiangiogenic therapy for Malignant brain tumors: does it still matter","volume":"25","author":"Pellerino","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-019-04117-z","article-title":"Bevacizumab-containing regimen in relapsed\/progressed brain tumors: a single-institution experience","volume":"35","author":"Schiavetti","year":"2019","journal-title":"Childs Nerv Syst"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1159\/000082921","article-title":"Gemcitabine combined with oxaliplatin (GEMOX) as second-line chemotherapy in patients with advanced ovarian cancer refractory or resistant to platinum and taxane","volume":"67","author":"Raspagliesi","year":"2004","journal-title":"Oncology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1530\/EJE-21-0137","article-title":"Prevalence and risk factors of hypothalamic\u2013pituitary dysfunction in infant and toddler childhood brain tumor survivors","volume":"185","author":"Lebbink","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2022.04.009","article-title":"Cross-translational models of late-onset cognitive sequelae and their treatment in pediatric brain tumor survivors","volume":"110","author":"Al Dahhan","year":"2022","journal-title":"Neuron"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3171\/2011.6.PEDS11158","article-title":"Resection of infantile brain tumors after neoadjuvant chemotherapy: the St. Jude experience","volume":"8","author":"Van Poppel","year":"2011","journal-title":"J Neurosurg Pediatr"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3171\/2014.11.PEDS14334","article-title":"Neoadjuvant chemotherapy for brain tumors in infants and young children","volume":"15","author":"Iwama","year":"2015","journal-title":"PED"},{"key":"B44","doi-asserted-by":"publisher","first-page":"100865","DOI":"10.1016\/j.bas.2022.100865","article-title":"Second-look surgery after pediatric brain tumor resection \u2013 Single center analysis of morbidity and volumetric efficacy","volume":"2","author":"Schmitz","year":"2022","journal-title":"Brain Spine"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1476411\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T05:29:10Z","timestamp":1747114150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1476411\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":44,"alternative-id":["10.3389\/fonc.2025.1476411"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1476411","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,5,13]]},"article-number":"1476411"}}